The availability of a species-specific monoclonal antibody that recognizes the low density lipoprotein (LDL) receptor of human but not hamster origin permitted assignment of the structural gene for the human receptor to chromosome 19. The antibody waes used to detect the human LDL receptor in a series of hamster-human somatic cell hybrids by two assays: (i) a structural assay that measured cellular incorporation of [35S]methionine into immunoprecipitable receptor and (ii) a functional assay that measured the rate of receptor-dependent uptake and degradation of the 12I-labeled anti-receptor monoclonal antibody. Both assays showed that the human LDL receptor was expressed in 15 out of 20 hybrid cell lines. Expression of the human LDL receptor was 100% concordant with the presence of human chromosome 19; all other human chromosomes showed at least 25% discordance. As expected, the gene for the LDL receptor (LDLR) is located on the same chromosome as the gene for the disease familial hypercholesterolemia, which has been previously mapped to chromosome 19 by pedigree studies and is caused by allelic mutations at the LDL receptor locus. The gene for apolipoprotein E, a ligand for the LDL receptor, is also known to be located on chromosome 19, raising the possibility of an evolutionary link between a protein ligand and its receptor.
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The low density lipoprotein (LDL) receptor plays a major role in controlling the level of cholesterol in plasma of humans and animals (1) . Located on the surface of hepatocytes and other cells, the receptor binds LDL, a cholesterol transport protein, and facilitates its entry into cells by receptormediated endocytosis. Inside the cell, LDL is degraded in lysosomes and its cholesterol is released for metabolic use.
By controlling the rate of degradation of plasma LDL, the LDL receptor determines the plasma level of the lipoprotein.
A common autosomal dominant disease, familial hypercholesterolemia, has been traced to a series of mutant alleles at the LDL receptor locus (2) . About 1 in 500 individuals is heterozygous for one of these defects. Heterozygotes ex- press half the normal number of LDL receptors and maintain plasma LDL-cholesterol levels about 2-fold above normal. Mapping the LDL receptor locus has become feasible as a result of purification of the receptor from bovine adrenal cortex (6) and the preparation of mouse monoclonal antibodies directed against the receptor (7) . One of the monoclonal antibodies, designated IgG-C7, recognizes the human and the bovine LDL receptor but does not recognize the LDL receptor of hamsters, mice, or other rodent species (7). The human LDL receptor binds 125I-labeled IgG-C7 (125I-IgG-C7) in amounts stoichiometric to the binding of LDL; i.e., there is one molecule of IgG-C7 bound for each molecule of LDL bound. The receptor-bound 125I-IgG-C7 is taken up by cells and degraded in lysosomes in a similar fashion to LDL.
Thus, measurements of the uptake and degradation of 125i-IgG-C7 by cells can be related to the number of human LDL receptors on the surface of a cell (7) . Inasmuch as monoclonal IgG-C7 does not recognize the hamster LDL receptor, it should be useful for detection of human receptors on the surfaces of hamster-human hybrid cells. This, in turn, should permit assignment of the human LDL receptor gene to a specific human chromosome.
In the current studies, we have used the IgG-C7 were studied by cellogel electrophoresis (11, 12) .
Monoclonal Antibody Against Human LDL Receptor. A species-specific mouse monoclonal antibody (IgG-C7) that binds to the human LDL receptor was prepared with the lymphocyte hybridoma technique (13) . IgG-C7 binds to the human and bovine LDL receptor, but it does not react with the LDL receptor of hamster, mouse, rat, rabbit, or canine cells (7) . IgG-2001, a mouse monoclonal antibody directed against an irrelevant antigen (Hemophilus influenza, type B) was prepared as described (13) . IgG-C7 was radiolabeled with 125I to specific activities of 5-17 x 103 cpm/ng of protein by the chloramine-T method (13) .
Cultures. Human, Chinese hamster, and hybrid cells were grown in monolayer culture at 37°C with 5% C02/95% air. On day 0 of growth, 8 x 104 cells were seeded into Petri dishes (60 x 15 mm) containing (each) 3 ml of medium A (Ham's F-12 medium supplemented with penicillin at 100 units/ml and streptomycin at 100 ,ug/ml) and 10% (vol/vol) fetal calf serum. After 2 or 3 days of growth, cells were switched to lipoprotein-deficient serum for 24 or 48 hr to induce synthesis of LDL receptors (14) .
Immunoprecipitation of LDL Receptors. and 10% lipoprotein-deficient serum. After 3 hr at 370C, monolayers were washed, and detergent extracts were prepared (15) . The extracts were incubated with immunocomplexes containing IgG-C7 or IgG-2001, and the precipitates were washed (15) . Pellets were dissolved in 8 M urea/0.2 M dithiothreitol and subjected to NaDodSO4/polyacrylamide gel electrophoresis and fluorography (15) .
Functional Assay for LDL Receptors. After 48 hr in lipoprotein-deficient serum, monolayers were incubated with 2 ml of Ham's F-12 medium containing 10% human lipoproteindeficient serum and either 125I-IgG-C7 (1 ,g/ml, 5-17 x 103 cpm/ng of protein) in the absence or presence of unlabeled IgG-C7 at 250 jxg/ml or 125I-labeled LDL (125I-LDL; 10 pxg/ml, 160 cpm/ng protein) (14) in the absence or presence of unlabeled LDL at 400 jig/ml. After 1-5 hr at 370C, total cellular uptake (surface-bound plus internalized) of _251-IgG-C7 or 125I-LDL and total amount of 125I-IgG-C7 or 125I-LDL degraded by the cells and excreted into the culture medium were measured (14) . High affinity uptake plus degradation was calculated by subtracting the 12 I-labeled ligand values obtained in the presence of unlabeled ligand from those obtained in its absence. LDL receptor studies were carried out on coded hybrid cell samples without knowledge of the human chromosome content.
RESULTS
Two types of assays were used to detect the human LDL receptor in hamster-human hybrids. In the immunoprecipitation assay, the cells were incubated with [35S]methionine under conditions of cholesterol deprivation, which elicits maximal synthesis of LDL receptors. Detergent-solubilized extracts were incubated with IgG-C7, and the immunoprecipitates were analyzed by NaDodSO4/polyacrylamide gel electrophoresis. The spectrum of results obtained is shown in Fig. 1 IgG-2001 (control IgG) . The washed immunoprecipitates were subjected to NaDodSO4 electrophoresis in a 7% slab gel. The gel was exposed to x-ray film for 4 days. Hybrids were scored on a 0 to 4+ scale as follows: hybrid A, 4+; hybrid E, 0; hybrid G, 1+. tein that was specifically immunoprecipitated by IgG-C7 (lane CHO). Some of the hamster-human hybrids synthesized relatively large amounts of the human receptor (hybrid A); other hybrids synthesized small but definite amounts (hybrid G). Both of these hybrids were scored positive in the assay (4+ and 1+, respectively, in Table 1 ). Other hybrids synthesized no detectable human receptor (hybrid E), and these were scored as negative (0 in Table 1) . A more quantitative estimate of the number of human LDL receptors was obtained from measurements of the rate at which the cells took up and degraded 125I-IgG-C7 (Fig. 2) .
CHO cells took up and degraded human 125I-LDL at a rapid rate, because of binding of human 125I-LDL to the hamster LDL receptor. The hybrid cells that expressed the human LDL receptor (hybrid A) also took up 125I-LDL but in amounts that were less than that of the CHO cells (Fig. 2A) . The inverse relationship was seen when the uptake of 1251_ IgG-C7 was examined. The hybrid cells took up 1251-IgG-C7, whereas the CHO cells did not (Fig. 2B) . Thus, the CHO cells were synthesizing the hamster LDL receptor, which binds 125I-LDL but not 125I-IgG-C7, whereas the hybrid cells were synthesizing the human receptor, which binds both 1251I-LDL and 1251I-IgG-C7. Presumably, these hybrid cells were also synthesizing hamster LDL receptor, but we have no way to make this determination.
These findings permitted the establishment of a quantitative screening assay for expression of the human receptor gene in the hamster-human hybrids. In each experiment, performed on a single day, the uptake of _251-IgG-C7 was measured in cells from a standard human fibroblast cell line (positive control), CHO cells (negative control), and one to four hybrid cell lines. The results in the hybrids are expressed as a percentage of the values in the control human fibroblasts studied on the same day. Among the 20 hybrids analyzed, the human LDL receptor (LDLR) was expressed in 15 and absent in 5 (Table 1 ). In all cells in which the human LDL receptor was detected by immunoprecipitation, the activity of the human LDL receptor could be verified with the functional assay. The only human chromosome that showed a concordant pattern of segregation with the human LDL receptor was chromosome 19. All other chromosomes were excluded by at least 5 (25%) discordant hybrids. The human chromosomes retained in each of the hybrids were usually present in 50-90% of the metaphases analyzed and sometimes in more than one copy per cell. For chromosome 19, the frequencies (average copy number per cell) are presented in Table 1 . There was complete concordance between the presence of chromosome 19 as determined cytologically and 2  8  2  2  8  10  4  3  5  2  2  1  13  6  13  13  4  5  1  2  0  3  3  4   14   8  13  16  7  9  20  19  20  20  17  20   70  42  65  80  41  45   9  12  4  0  6  3  1  5   --+   pg   8  9  5  10  15  10  12  11  5  4  3  4  5  5  2  2  5  6  10  5  0  5  2  2   0   1  2  1  0  0  3  3   9  1  4  3   7   8  5  7  12  6  0  5  5  5  7  20  20  18  20  20  20  20  20  19  18  17   35  40  28  35  60  30  0  25  26  28  44 t+, Presence of chromosome in at least 10% of cells; -, absence of chromosome; P, presence of part of chromosome as specified by a-g: a, 3qter -cen--qter; b, lpter--p3200; c, 15q14-* qter; d, 22pter-3 q13.31; e, 8pter -q22; f, llpll-* qter; g, Xp22.2--qter; R, rearranged chromosome. P and R were excluded from calculating the ratio of discordant hybrids. antibody IgG-C7 recognizes the unprocessed 120,000-dalton nal antibody with specificity for the LDL receptor of human precursor of the human receptor (15) . If the hamster-human but not hamster origin was used to detect the expression of hybrid cells were accumulating this precursor in the absence the human LDLR gene in a panel of hybrids. Species-specific of human chromosome 19, the immunoprecipitation reacmonoclonal antibodies have been used previously in contions should have revealed it. These data strongly suggest junction with interspecies somatic cell hybrids for the chrothat the hamster enzymes are able to process the human mosomal localization of genes for other cell surface antigens LDL receptor precursor and that human chromosome 19
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The current results agree with family linkage data that The LDL receptor undergoes complex posttranslational place the familial hypercholesterolemia locus (FHC) on processing en route from its site of synthesis in the endoplaschromosome 19 (3, 4) . FHC is linked to the gene for complemic reticulum to its site of function on the cell surface (15, ment component 3 (C3) at a distance of 20 centimorgans, 21). The receptor gains both N-linked and 0-linked carbohywith a lod score of 4.75 (22) . C3 has previously been assigned drates, which causes its apparent molecular weight to into chromosome 19 by somatic cell hybrid studies (5) and increase from 120,000 to 160,000 as estimated from NaDodSO4 directly by linkage to the polymorphic enzyme locus for pepgels (15, 21) . It is therefore possible that human chromosome tidase D (PEPD) (23 (26) . This suggests that APOE and LDLR (which is equivalent to FHC) are on opposite sides of C3. The chromosomal location of the gene for apoprotein B is not yet known.
The possibility of a syntenic localization of plasma proteins and their cell surface receptors is intriguing. The chromosomal loci for only two other cell surface receptors that undergo receptor-mediated endocytosis are known-the human receptor for transferrin (located on chromosome 3) (17) and the human receptor for epidermal growth factor (located on chromosome 7) (27, 28) . The gene for human transferrin, the ligand for the transferrin receptor, has been provisionally mapped to the same chromosome as the gene for its receptor-i.e., chromosome 3 (29) . The 
